FDA Approves LITHIUM CARBONATE — Hikma Pharmaceuticals USA Inc.

Hikma Pharmaceuticals USA Inc. has announced the initiation of 180-day generic exclusivity for lithium carbonate oral tablets, replacing the Teva branded product. This move is expected to impact the market by offering prescribers and payors a new biosimilar-style pricing alternative following the expiration of the reference product patent.